Skip to main content
. 2024 Jan 23;15:1329636. doi: 10.3389/fphar.2024.1329636

FIGURE 3.

FIGURE 3

Schematic diagram of albumin nanoparticles targeting tumor cells via the GP60 and SPARC pathways. When albumin nanoparticles are circulated to tumor tissues via intravenous injection, albumin nanoparticles will rely on GP60 receptors to penetrate vascular endothelial cells and enter the tumor microenvironment. Then, these albumin nanoparticles will interact with the SPARC protein secreted by tumor cells, ultimately achieving the effect of targeting tumor cells.